A study in Nature Communications identified MARCH2 as a key molecular protector against chemotherapy-induced heart damage from doxorubicin. The work describes how MARCH2 stabilizes cardiac cells by clearing specific cellular components, preventing a pathway that can culminate in cardiomyopathy. Doxorubicin-associated cardiotoxicity remains a major limitation in oncology treatment, often forcing dose reductions or agent switching. Mechanistic insights like this are frequently used to develop adjunct strategies that preserve anti-cancer efficacy while reducing cardiac risk. The findings highlight a protein-level handle for intervention rather than a broad protective effect, positioning MARCH2-related biology as a potential target for future cardioprotection approaches. If subsequent studies support therapeutic modulation of MARCH2 in relevant settings, it could become an important addition to the cardio-oncology toolbox.